




Patent Docket P1089R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Lam et al. Serial No.: 09/724,868 Filed: November 28, 2000 For: ANTIBODY FORMULATION	Group Art Unit: 1644 Examiner: M. Dibrino Confirmation No. 8389 Customer No. 09157 I hereby certify that this transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450 on: March 4, 2005  Janet Tse
---	---

**APPLICATION FOR PATENT TERM ADJUSTMENT
UNDER 37 C.F.R. § 1.705(b)**

Mail Stop ISSUE FEE
COMMISSIONER FOR PATENTS
P.O.BOX 150
Alexandria, VA 22313-1450

Dear Sir:

Applicants request reconsideration of the Director's determination of patent term adjustment (PTA) as communicated in the Notice of Allowance mailed on December 7, 2004. In particular, applicant requests restoration of 107 days of PTA erroneously charged against applicant under 37 C.F.R. § 1.704(b).

This application is filed concurrently with the payment of the Issue Fee and is therefore timely. The Director is authorized to charge applicant's Deposit Account No. 07-0630 for the required fee as specified in § 1.18(e) (\$200.00).

Facts

1. Attached is a printout of the Office's determination of PTA for this application, as provided on PAIR. The net PTA shown on the printout is 370 days.
2. (§ 1.705)(2)(i) For the following reasons, the correct PTA to which this application is entitled is 477 days.
3. (§ 1.705)(2)(ii). The examination delays under §§ 1.702(a) and 1.703, which are correctly shown on the attached PAIR printout, are the following:

- 490 days for failing to mail the Restriction Requirement within 14 months of filing, for the interval between November 28, 2000 and June 2, 2003.

The sum of these delays is 490 days (§ 1.703(f)).

4. (§ 1.705)(2)(iii) This application is not subject to a terminal disclaimer.
5. (§ 1.705)(2)(iv)(A) The reductions under § 1.704 as shown on the attached PAIR printout which applicant believes to be correct are the following:
 - 13 days for failing to file a Response to a Non-Final Office Action within three months, for the interval between September 3, 2004 and September 16, 2004.

The sum of this delay is 13 days.

6. The PAIR entry for an Information Disclosure Statement (IDS) on May 28, 2004 does not correspond to a failure by the applicant to engage in reasonable efforts to conclude prosecution.
 - (a) On February 13, 2001, applicant filed an IDS in compliance with 37 C.F.R. § 1.97 and 1.98. Attached is a postcard returned to the applicant and stamped by the Office indicating that the Office did in fact receive the IDS.
 - (b) On May 28, 2004, the examiner contacted applicant by phone and indicated that she was reviewing the IDS but could not read the copy scanned into the Office's Image File Wrapper system. At the examiner's express request, applicant faxed a copy of the IDS previously filed on February 13, 2001 to the examiner (copies attached herewith).

- (c) The papers filed on May 28, 2004 were identical to the IDS filed on February 13, 2001. However, these papers were erroneously entered into the PALM database as a new or supplemental IDS.

Discussion

Applicant believes that the act of filing a duplicate copy of a paper previously submitted to comply with an examiner's request does not constitute a failure to engage in reasonable efforts to conclude prosecution. In this instance, the IDS in question was first properly filed on a date which, under PTO rules and practice, did not result in such a failure. Accordingly, the submission of the papers filed on May 28, 2004 should not result in a reduction of PTA under § 1.704.

The duplicate IDS was not a submission to rectify an omission in an earlier filing (§ 1.704(c)(7), a supplemental reply (§ 1.704(c)(8)), or a new IDS falling outside the exception of § 1.704(d). Instead, it contained only copies of papers already filed with the Office, provided for the examiner's convenience and at the examiner's request.

The proper treatment of the submission is indicated in the discussion of § 1.704(c)(8) at M.P.E.P. § 2732, which states that "[§] 1.704(c)(8) does not apply to a supplemental reply or other paper that was expressly requested by the examiner." For an expressly requested amendment, for example, "the examiner will have the paper processed so that it is included as part of an interview summary or examiner's amendment and not a separate paper for PALM to flag in the patent term adjustment calculation." M.P.E.P. 8th ed., Rev. 2, at 2700-20, paragraph bridging columns.

The same procedure should have been followed with the papers submitted on May 28, 2004. Because the papers were expressly requested by the examiner, and because they did not constitute any new action corresponding to a failure to engage in reasonable efforts to conclude prosecution, the PALM entry indicating that the submission was a new IDS was in error.

Conclusion

Applicant respectfully requests correction of the Office's records and adjustment of the Office's calculation of term adjustment by the addition of 107 days of patent term adjustment.

Respectfully submitted,
GENENTECH, INC.


Date: March 4, 2005

By: Lee Tan
Lee K. Tan, Ph.D.
Reg. No. 39,447
Telephone No. (650) 225-4462




United States Patent and Trademark Office

Home | Site Index | Search | FAQ | Glossary | Guides | Contacts | eBusiness | eBiz alerts | News | Help



PATENT APPLICATION INFORMATION RETRIEVAL



PAIR

FAQ

Help

Feedback

Other Links

E-Business
Center Patents

Employee
Locator

Class/Subclass
GAU Information

Information
Contacts

Printer Friendly Version

Patent Term Adjustment (PTA) for application number: 09/724,868

			Days
Filing or 371(c) Date:	11-28-2000	USPTO Delay (PTO):	490
Issue Date of Patent:	-	Three Years:	-
Pre-Issue Petitions (days):	+0	Applicant Delay (APPL):	120
Post-Issue Petitions (days):	+0	Total PTA:	370
USPTO Adjustment (days):	+0	Explanation of Calculations	

Select Search Option

Continuity Data

Search

File History

Image File Wrapper


Publication Review

Patent Term Adjustment History

Date	Contents Description	PTO (days)	APPL (days)
12-07-2004	Mail Notice of Allowance		
12-07-2004	Issue Revision Completed		
12-07-2004	Notice of Allowance Data Verification Completed		
12-07-2004	Notice of Allowability		
09-16-2004	Substitute Specification Filed		
09-16-2004	Affidavit(s) (Rule 131 or 132) or Exhibit(s) Received		
09-27-2004	Date Forwarded to Examiner		
09-16-2004	Response after Non-Final Action		13
09-16-2004	Request for Extension of Time - Granted		↑
09-16-2004	Workflow incoming amendment IFW		↑
05-28-2004	Information Disclosure Statement (IDS) Filed		107
06-03-2004	Mail Non-Final Rejection		↑
06-01-2004	Non-Final Rejection		↑
02-21-2004	Date Forwarded to Examiner		↑
02-11-2004	Response to Election / Restriction Filed		↑
02-11-2004	Request for Extension of Time - Granted		
12-09-2003	Mail Restriction Requirement		
12-08-2003	Requirement for Restriction / Election		
09-17-2003	Date Forwarded to Examiner		
08-11-2003	Response to Election / Restriction Filed		
08-11-2003	Request for Extension of Time - Granted		
06-05-2003	CRF Is Good Technically / Entered into Database		

06-02-2003	Mail Restriction Requirement	490	
06-02-2003	Requirement for Restriction / Election	↑	
03-04-2003	Case Docketed to Examiner in GAU	↑	
03-04-2003	Dispatch from OIPE to Corps - U-P-R-D Application	↑	
01-18-2001	Correspondence Address Change	↑	
12-18-2000	IFW Scan & PACR Auto Security Review	↑	
11-28-2000	Initial Exam Team nn	↑	

[|.HOME|](#)[|INDEX|](#)[|SEARCH|](#)[|eBUSINESS|](#)[|CONTACT US|](#)[|PRIVACY STATEMENT](#)



In re Application of: Lam et al.
Serial No.: 09/724,868
Filed On: 28 November 2000
Mailed On: February 13, 2001

Docket No.: P1089R1C1
By: Lee K. Tan
Reg. No.: 39,447

The following has been received in the U.S. Patent Office on the date stamped:

☒ Information Disclosure Statement
☒ PTO 1449 Form (-0- copies of references enclosed)
☒ Certificate of Mailing

In re Application of: Lam et al.
Serial No.: 09/724,868
Filed On: 28 November 2000
Mailed On: February 13, 2001

Docket No.: P1089R1C1
By: Lee K. Tan
Reg. No.: 39,447



The following has been received in the U.S. Patent Office on the date stamped:

☒ Information Disclosure Statement
☒ PTO 1449 Form (-0- copies of references enclosed)
☒ Certificate of Mailing



BEST AVAILABLE COPY



Patent Docket P1089R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Lam et al. Serial No.: 09/724,868 Filed: 28 November 2000 For: ANTIBODY FORMULATION	Group Art Unit: Unassigned Examiner: Unassigned <div style="border: 1px solid black; padding: 5px;"><p style="text-align: center; margin: 0;">CERTIFICATE OF MAILING</p><p style="font-size: small; margin: 0;">I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p><p style="text-align: center; margin: 5px 0;">February 13, 2001</p><p style="text-align: center; margin: 0;"><i>Ann Savelli</i> Ann Savelli</p></div>
--	---

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

- ☒ **37 CFR §1.97(b)**
- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
 - within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
 - before the mailing of the first Office action on the merits; or
 - before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.
- ☐ **37 CFR §1.97(c)**
- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.
- ☐ **37 CFR §1.97(d)**
- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/097,171, filed June 6, 1998 and relied upon in this application for an earlier filing date under 35 USC §120.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: February 13, 2001

By: Lee K. Tan
Lee K. Tan
Reg. No. 39,447
Telephone No. (650) 225-4462



09157

PATENT TRADEMARK OFFICE

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1089R1C1

Serial No.

09/724,868

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Lam et al.

Filing Date

28 Nov 2000

Group

Unassigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,093,606	06.06.78	Coval, M.			
	* 2	4,457,916	03.07.84	Hayashi et al.			
	* 3	4,499,073	12.02.85	Tenold, R.			
	* 4	4,877,608	31.10.89	Lee, T. et al.			
	* 5	4,940,782	10.07.90	Rup et al.			
	* 6	5,032,405	16.07.91	Huang, H. et al.			
	* 7	5,036,049	30.07.91	Audhya, T. et al.			
	* 8	5,096,885	17.03.92	Pearlman et al.			
	* 9	5,147,637	15.09.92	Wright et al.			
	*10	5,149,653	22.09.92	Roser			
	*11	5,215,743	01.06.93	Singh, M. et al.			
	*12	5,262,296	16.11.93	Ogawa, E. et al.			
	*13	5,307,640	03.05.94	Fawzy et al.			
	*14	5,399,670	21.03.95	Bhattacharya, P. et al.			
	*15	5,506,342	09.04.96	Reno et al.			
	*16	5,580,856	03.12.96	Prestrelski et al.			
	*17	5,589,167	31.12.96	Cleland et al.			
	*18	5,608,038	04.03.97	Eibl et al.			
	*19	5,654,403	05.08.97	Smith et al.			
	*20	5,730,980	24.03.98	Ulevitch et al.			
	*21	5,736,137	07.04.98	Anderson et al.			
	*22	5,770,700	23.06.98	Webb et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	*23	AU-B-30771/89	07.09.89	AUSTRALIA			
	*24	2,138,853	29.06.95	CANADA			
	*25	303,746	22.02.89	EPO			
	*26	391,444	10.10.90	EPO			
	*27	661,060	05.07.95	EPO (WITH ENGLISH ABSTRACT)			
	*28	WO 89/09402	05.10.89	PCT (WITH ENGLISH ABSTRACT)			
	*29	WO 89/11297	30.11.89	PCT			
	*30	WO 90/11091	04.10.90	PCT			
	*31	WO 92/22653	23.12.92	PCT			
	*32	WO 94/11026	26.05.94	PCT			
	*33	WO 94/26302	24.11.94	PCT			

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1089R1C1

Serial No.

09/724,868

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Lam et al.

Filing Date

28 Nov 2000

Group

Unassigned

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	*34	WO 96/41164	19.12.96	PCT				
	*35	WO 97/04801	13.02.97	PCT				
	*36	WO 97/04807	13.02.97	PCT				
	*37	WO 97/17087	15.05.97	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	*38	Akers, M., "Considerations in selecting antimicrobial preservative agents for parenteral product development" <u>Pharmaceutical Technology</u> pps. 36-40;43-44;46 (May 1984)						
	*39	Albelda et al., "Integrins and other cell adhesion molecules" <u>FASEB-J</u> 4(11):2868-2880 (1990)						
	*40	Arakawa et al., "Protein-Solvent Interactions in Pharmaceutical Formulations" <u>Pharmaceutical Research</u> 8(3):285-291 (1991)						
	*41	Bam et al., "Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique" <u>Pharm. Res.</u> 12:2-11 (1995)						
	*42	Beauvais et al., "Both Glassy State and Native Structure are Required for Storage Stability of Lyophilized Interleukin-1 Receptor Antagonist" <u>Pharm. Res.</u> (Abstract #2007) 12(9):S-80 (1995)						
	*43	Bogard et al., "Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy" <u>Seminars in Nuclear Medicine</u> 19(3):202-220 (1989)						
	*44	Chang and Fischer, "Development of an Efficient Single-Step Freeze-Drying Cycle for Protein Formulations" <u>Pharm. Res.</u> 12(6):831-837 (1995)						
	*45	Chang et al., "Development of a Stable Freeze-dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist" <u>Pharmaceutical Research</u> 13(2):243-248 (1996)						
	*46	Chang et al., "Nucleotide sequence of the alkaline phosphatase gene of Escherichia Coli" <u>Gene</u> 44:121-125 (1986)						
	*47	Clarke et al., "Lability of Asparagine and Aspartic Acid Residues in Proteins and Peptides" <u>Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein Degradation</u> , T.J. Ahern and M.C. Manning, New York:Plenum Press, Chapter 1, pps. 1-29 (1992)						
	*48	Cleland and Jones, "Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers" <u>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</u> 22:514-515 (1995)						
	*49	Cleland et al., "Mechanisms of Nonionic Surfactant Stabilization of Proteins" <u>Pharmaceutical Research</u> (Abstract #BIOTEC 2012; Ninth Annual Meeting of the American Association of Pharmaceutical Scientists held in San Diego, CA on November 6-10, 1994) 11(10 Suppl.):S73 (1994)						
	*50	Cleland et al., "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation" <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> 10(4):307-377 (1993)						
	*51	Draber et al., "Stability of Monoclonal IgM Antibodies Freeze-Dried in the Presence of Trehalose" <u>Journal of Immunological Methods</u> 181(1):37-43 (1995)						
	*52	Hernandez et al., "Role of neutrophils in ischemia-reperfusion-induced microvascular injury" <u>Am. J. Physiol.</u> 253(3 Pt 2):H699-H703 (1987)						
	*53	Hildreth et al., "A Human Lymphocyte-associated Antigen Involved in Cell-mediated Lympholysis" <u>European Journal of Immunology</u> 13:202-208 (1983)						

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1089R1C1

Serial No.

09/724,868

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Lam et al.

Filing Date

28 Nov 2000

Group

Unassigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*54	Hildreth et al., "The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): functional effects of subunit-specific monoclonal antibodies" <u>J. Immunol.</u> 134:3272-3280 (1985)
*55	Hynes, "Integrins: versatility, modulation, and signaling in cell adhesion" <u>Cell</u> 69(1):11-25 (1992)
*56	Izutsu et al., "The effects of additives on the stability of freeze-dried β -galactosidase stored at elevated temperature" <u>Intl. J. Pharmaceutics</u> 71:137-146 (1991)
*57	Jutila et al., "Inflammation-induced endothelial cell adhesion to lymphocytes, neutrophils, and monocytes" <u>Transplantation</u> 48(5):727-731 (1989)
*58	Kossiakoff, A.A., "Tertiary Structure Is a Principal Determinant to Protein Deamidation" <u>Science</u> 240:191-194 (1988)
*59	Lam et al., "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery" <u>American Association of Pharmaceutical Scientists, Western Regional Meeting, South San Francisco, CA</u> (Abstract #F-22 and poster presented at the meeting) (April 24-25, 1997)
*60	Lam et al., "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery" <u>Proceedings of the 24th International Symposium on Controlled Release of Bioactive Materials</u> 24:759-760 (June 15-19, 1997)
*61	Lam et al., "Pitfalls in Development of Multi-Dose Liquid Formulations for Three Protein Pharmaceuticals" <u>ACS National Meeting, New Orleans</u> (Abstract #137 and slides presented) (March 24-28, 1996)
*62	Li et al., "Aggregation and Precipitation of Human Relaxin Induced by Metal-Catalyzed Oxidation" <u>Biochemistry</u> 34(17):5762-5772 (1995)
*63	Manning et al., "Stability of Protein Pharmaceuticals" <u>Pharm. Res.</u> 6(11):903-918 (1989)
*64	Mileski et al., "Inhibition of CD18-dependent neutrophil adherence reduces organ injury after hemorrhagic shock in primates" <u>Surgery</u> 108:206-212 (1990)
*65	Nielsen, et al., "Stability of Freeze Dried Horseradish Peroxidase Conjugated Monoclonal Antibodies Used in Diagnostic Serology" <u>Journal of Immunoassay</u> 16(2):183-197 (1995)
*66	Novak et al., "The tolerance and safety of intravenously administered benzyl alcohol in methylprednisolone sodium succinate formulations in normal human subjects" <u>Toxicology and Applied Pharmacology</u> 23(1):54-61 (Sep 1972)
*67	Pearlman et al., "Analysis of Protein Drugs" <u>Peptide and Protein Drug Delivery</u> , Vincent H. L. Lee, Marcel Dekker, Inc., Chapter 6, pps. 247-301 (1991)
*68	Picken et al., "Nucleotide sequence of the gene for heat-stable enterotoxin II of Escherichia coli" <u>Infection and Immunity</u> 42(1):269-275 (1983)
*69	Pikal et al., "The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone" <u>Pharm. Res.</u> 8:427-436 (1991)
*70	Pikal, M., "Freeze-Drying of Proteins, Part 2: Formulation Selection" <u>Biopharm.</u> 3(9):26-30 (1990)
*71	Rao and Kroon, "Orthoclone OKT3: Chemical Mechanisms and Functional Effects of Degradation of a Therapeutic Monoclonal Antibody" <u>Stability and Characterization of Protein and Peptide Drugs: Case Histories</u> , eds. John Wang and Rodney Pearlman, New York:Plenum Press pps. 135-158, chapter 4, (1993)
*72	Reilly et al., "Oral delivery of antibodies: future pharmacokinetic trends" <u>Clin. Pharmacokinet.</u> 32(4):313-323 (1997)
*73	Sapan, "Immunoglobulin stability" <u>Biotechnol. Appl. Biochem.</u> 25:9-12 (1997)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unassigned

Yates, "Protein Structure Analysis by Mass Spectrometry" Methods in Enzymology 271:351-377 (1996)

USCOMM-DC 80-398.

GENENTECH, INC
GENENTECH, INC.
GENENTECH, INC.
GENENTECH, INC.



1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-4462
TWX 9103717168

LEGAL DEPARTMENT

FAX NUMBERS (650) - 952-9881 OR (650) - 952-9882

DATE: May 28, 2004

Please deliver the following page(s) to:

NAME: Examiner M. Dibrino, Group Art Unit 1644

FIRM: U.S. Patent and Trademark Office

NUMBER TRANSMITTING TO: (571)273-0842

FROM: Lee K. Tan, Ph.D.; Reg. No. 39,447

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 9

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. This information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the documents to us and the retransmission of them to the intended recipient.

COMMENTS:

Re: Genentech Docket No.: P1089R1C1
Lam et al.
Serial No. 09/724,868
Filed: November 28, 2000
Title: ANTIBODY FORMULATION
Confirmation No.: 8389
Genentech Customer No.: 09157

Per your voice mail request this morning, attached is a copy of the IDS, form 1449 and PTO stamped postcard receipt.